Sweden-based Hansa Biopharma AB has appointed Magnus Korsgren as head of research and development to advance the company’s pipeline of drug candidates for rare immunologic diseases. He brings more than 15 years of experience in preclinical and clinical drug development from a variety of companies including Ferring Pharmaceuticals SA, AstraZeneca Plc, BioInvent International AB and Novartis. Dr Korsgren is board certified in clinical pharmacology.
Hansa Biopharma announced the appointment on 1 March 2021.
Copyright 2021 Evernow Publishing Ltd